Home
News/PR
Global Liquid Biopsy Market

Customizations Possible - Country-wise reports, Additional company profiles, Country/Regional reports and Other Customizations. Special Discounts Available. Global Liquid Biopsy Market Size, Share, Growth & Trends Report Segmented by Technology (NGS, dPCR), Biomarker (ctDNA, cfDNA, CTCs), Application (Lung, Breast, Colorectal, Prostate, Prenatal), Sample (Blood, Urine), Product & Service, End-user, Analysis & Regional Forecast to 2031

Global Liquid Biopsy Market Size, Share, Growth & Trends Report Segmented by Technology (NGS, dPCR), Biomarker (ctDNA, cfDNA, CTCs), Application (Lung, Breast, Colorectal, Prostate, Prenatal), Sample (Blood, Urine), Product & Service, End-user, Analysis & Regional Forecast to 2031

The global liquid biopsy market size is set to grow at 12% CAGR over the next 5 years. Rising global cancer incidence and growing demand for early cancer detection; increasing adoption of precision medicine and targeted therapies, advancements in NGS, PCR, and multi-omics technologies; and growing preference for minimally invasive diagnostic procedures, are some of the key factors driving the market’s growth. Furthermore, expansion of multi-cancer early detection (MCED) testing, growing demand for minimal residual disease (MRD) monitoring, and increasing adoption across emerging healthcare markets offer numerous growth opportunities in this market. To learn more about the research report, download a sample report.

liquid-biopsy-market-transforming-new-era-for-cancer-diagnosis

transparent

600

#12bece

‌
DESCRIPTION
TABLE OF CONTENTS
METHODOLOGY
Segmentation

Liquid biopsy is a minimally invasive diagnostic technique that detects and analyzes cancer-related biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), RNA, and exosomes, from body fluids including blood, urine, or cerebrospinal fluid. Unlike traditional tissue biopsies, liquid biopsy enables real-time disease monitoring with lower procedural risk and faster sample collection. The technology is increasingly used for early cancer detection, therapy selection, treatment response monitoring, recurrence surveillance, and minimal residual disease (MRD) assessment. Advancements in next-generation sequencing (NGS) and molecular diagnostics are expanding its applications across precision oncology, companion diagnostics, and multi-cancer early detection testing.

Advancements in NGS, PCR, and multi-omics technologies drives the liquid biopsy market

Advancements in next-generation sequencing (NGS), polymerase chain reaction (PCR), and multi-omics technologies are significantly driving the growth of the liquid biopsy market by improving the sensitivity, accuracy, and clinical utility of non-invasive cancer diagnostics. NGS technologies enable comprehensive genomic profiling by detecting multiple genetic alterations, including mutations, copy number variations, and gene fusions, from small quantities of circulating tumor DNA (ctDNA). This has expanded the use of liquid biopsy in precision oncology, companion diagnostics, and treatment selection. Increasing commercialization and adoption of NGS-based liquid biopsy solutions is accelerating the growth of the liquid biopsy market. For instance, in July 2025, Fortis Healthcare and Agilus Diagnostics launched a second Genexus system in India to strengthen rapid genomic cancer testing and liquid biopsy capabilities. Additionally, in September 2024, Pillar Biosciences partnered with AstraZeneca to expand access to rapid NGS-based liquid biopsy testing across Europe and the UK.

Similarly, advanced PCR technologies such as digital PCR (dPCR) and real-time PCR are enhancing the detection of low-frequency mutations with high specificity, supporting applications in minimal residual disease (MRD) monitoring, recurrence detection, and therapy response assessment. These technologies provide faster turnaround times and cost-effective testing solutions, further accelerating adoption in clinical settings. Companies are increasingly enhancing automation and sensitivity of PCR-based liquid biopsy workflows. For instance, in October 2024, QIAGEN expanded its automated liquid biopsy portfolio to support downstream digital PCR and molecular testing applications. Additionally, in July 2024, Bio-Rad Laboratories highlighted advancements in droplet digital PCR (ddPCR) technologies for ultra-sensitive biomarker detection and oncology research.

In addition, the emergence of multi-omics approaches integrating genomics, transcriptomics, proteomics, and epigenomics is improving the overall diagnostic accuracy of liquid biopsy assays. Multi-omics platforms provide deeper insights into tumor biology and disease progression, enabling more personalized treatment strategies. Continuous innovation in molecular diagnostics, bioinformatics, and AI-driven data analysis is expected to further strengthen the clinical adoption and commercialization of liquid biopsy technologies globally.

Liquid Biopsy Market

To learn more about this report, download the PDF brochure

Growing demand for minimal residual disease (MRD) monitoring presents a significant growth opportunity

MRD refers to the small number of cancer cells that may remain in the body after treatment and can potentially lead to disease recurrence. Traditional imaging and tissue biopsy methods often face limitations in detecting residual disease at very low levels, creating demand for highly sensitive liquid biopsy technologies capable of identifying ctDNA and molecular biomarkers in real time. As a result, healthcare providers are increasingly adopting liquid biopsy assays for post-treatment surveillance, recurrence monitoring, and therapy response assessment.

Advancements in NGS and dPCR technologies are further enhancing the sensitivity and accuracy of MRD testing, enabling earlier detection of relapse and more personalized treatment decisions. Pharmaceutical companies and diagnostic developers are also integrating MRD monitoring into clinical trials and precision oncology programs to improve patient stratification and optimize targeted therapies. In addition, growing regulatory support and increasing clinical evidence validating MRD-guided treatment approaches are expected to accelerate commercialization and adoption of liquid biopsy-based MRD solutions. Consequently, rising demand for non-invasive longitudinal cancer monitoring is expected to create substantial long-term growth opportunities for market participants.

Market participants are increasingly investing in strategic collaborations and commercialization initiatives to strengthen MRD testing capabilities and expand precision oncology applications. For instance, in April 2026, Tempus partnered with Predicta Biosciences to improve access to ultrasensitive whole-genome sequencing assays for hematologic malignancies and MRD monitoring. Additionally, in June 2025, QIAGEN expanded its MRD testing portfolio through new strategic partnerships focused on advancing oncology and liquid biopsy applications. Furthermore, in May 2024, Personalis announced commercialization initiatives for its cancer MRD testing solutions, highlighting growing industry focus on longitudinal cancer monitoring and personalized treatment strategies.

Liquid Biopsy Market - Segmentation

To learn more about this report, download the PDF brochure

Technology Segment Outlook

The liquid biopsy market is segmented by technology into next-generation sequencing (NGS), digital polymerase chain reaction (dPCR), and others, based on the molecular analysis platform used for biomarker detection and genomic profiling. NGS represents the largest and fastest-growing segment owing to its ability to perform comprehensive genomic analysis, detect multiple mutations simultaneously, and support precision oncology applications such as companion diagnostics, early cancer detection, and MRD monitoring.

dPCR is gaining significant adoption due to its high sensitivity, accuracy, and ability to detect low-frequency mutations from ctDNA, particularly in treatment monitoring and recurrence detection. The others’ segment includes technologies such as microarrays, fluorescence in situ hybridization (FISH), and emerging multi-omics platforms used in specialized research and diagnostic applications. Continuous advancements in molecular diagnostics and bioinformatics are further driving innovation across all technology segments.

Regional Outlook: North America maintains its leading position in the liquid biopsy market due to strong presence of leading companies, high adoption of NGS, & favorable reimbursement policies

North America is the largest market owing to the strong presence of leading liquid biopsy companies, high adoption of NGS, favorable reimbursement policies, and increasing utilization of precision oncology solutions across the US and Canada. Europe represents a significant market driven by growing cancer screening initiatives, expanding genomic medicine programs, and increasing investments in molecular diagnostics research. Asia-Pacific is expected to witness the fastest growth during the forecast period due to rising cancer incidence, improving healthcare infrastructure, expanding access to advanced diagnostic technologies, and increasing investments in precision medicine across countries such as China, Japan, India, and South Korea.

Competitive Landscape Analysis

The global liquid biopsy market is marked by the presence of established and emerging market players such as

Liquid Biopsy Market - Key Players Analysis

Get a sample report for competitive landscape analysis

Hoffmann-La Roche Ltd (Switzerland)
Illumina, Inc. (US)
Guardant Health, Inc. (US)
Myriad Genetics, Inc. (US)
Natera, Inc. (US)
Exact Sciences Corporation (US)
QIAGEN (Netherlands)
Bio-Rad Laboratories, Inc. (US)
Sysmex Corporation (Japan)
Thermo Fisher Scientific Inc. (US)

Growth strategies adopted by players to establish their foothold in the liquid biopsy market

Players operating in this market are adopting various growth strategies such as new product launches and approvals; acquisitions; expansions; and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

In May 2026, Natera announced presentation of 35 oncology studies at ASCO 2026 focused on Signatera MRD testing, treatment monitoring, and longitudinal disease management across multiple solid tumor indications, strengthening clinical validation of ctDNA-based precision oncology applications
In March 2026, Illumina and Labcorp expanded their precision oncology collaboration to co-commercialize liquid biopsy and comprehensive genomic profiling assays for hospitals and health systems, improving access to decentralized molecular testing and companion diagnostics
In June 2025, QIAGEN partnered with GENCURIX to develop oncology assays for the QIAcuityDx digital PCR platform supporting tissue and liquid biopsy applications, strengthening high-sensitivity mutation detection and decentralized cancer testing capabilities
In April 2025, Guardant Health collaborated with Pfizer to support development and commercialization of cancer therapies using the Guardant Infinity smart liquid biopsy platform, enhancing biomarker-driven drug development and precision oncology workflows
In May 2024, Personalis started commercialization collaboration with Tempus for the NeXT Personal MRD liquid biopsy assay supporting cancer recurrence and immunotherapy monitoring applications, expanding access to ultrasensitive personalized ctDNA testing in oncology care
In November 2023, Illumina launched the TruSight Oncology 500 ctDNA v2 liquid biopsy assay with improved sensitivity, faster turnaround time, and streamlined workflow capabilities for comprehensive genomic profiling and precision oncology applications

Report Scope

Report Metric	Details
Base Year Considered	2025
Historical Data	2024 – 2025
Forecast Period	2026 – 2031
Growth Rate	12%
Segment Scope	Product & Service, Technology, Biomarker Type, Sample Type, Application, End User
Regional Scope	North America (US & Canada) Europe (UK, Germany, France, Italy, Spain, Rest of Europe) Asia Pacific (China, India, Japan, Rest of Asia Pacific) Latin America Middle East & Africa
Market Drivers	Rising global cancer incidence and growing demand for early cancer detection Increasing adoption of precision medicine and targeted therapies Advancements in NGS, PCR, and multi-omics technologies Growing preference for minimally invasive diagnostic procedures Expanding applications in treatment monitoring and recurrence detection Increasing use of liquid biopsy in companion diagnostics and clinical trials
Attractive Opportunities	Expansion of multi-cancer early detection (MCED) testing Growing demand for minimal residual disease (MRD) monitoring Increasing adoption across emerging healthcare markets Integration of AI and bioinformatics for genomic interpretation
Key Companies Mapped	F. Hoffmann-La Roche Ltd (Switzerland); Illumina, Inc. (US); Guardant Health, Inc. (US); Myriad Genetics, Inc. (US); Natera, Inc. (US); Exact Sciences Corporation (US); QIAGEN (the Netherlands); Bio-Rad Laboratories, Inc. (US); Sysmex Corporation (Japan); and Thermo Fisher Scientific Inc. (US); among others
Report Highlights	Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis

Global Liquid Biopsy Market Segmentation

This report by Medi-Tech Insights provides the size of the global liquid biopsy market at the regional and country-level from 2024 to 2031. The report further segments the market by product & service, technology, biomarker type, sample type, application, and end user.

Market Size & Forecast (2024-2031), By Product & Service, USD Billion

Kits & Reagents
Instruments
Software & Services

Market Size & Forecast (2024-2031), By Technology, USD Billion

Next-Generation Sequencing (NGS)
PCR & Digital PCR (dPCR)
Others

Market Size & Forecast (2024-2031), By Biomarker Type, USD Billion

Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-Free DNA (cfDNA)
Exosomes/Microvesicles
Others

Market Size & Forecast (2024-2031), By Sample Type, USD Billion

Blood
Urine
Others

Market Size & Forecast (2024-2031), By Application, USD Billion

Oncology
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
Non-Cancer Applications
- Prenatal Testing
- Transplant Monitoring
- Infectious Diseases
- Neurological Disorders

Market Size & Forecast (2024-2031), By End User, USD Billion

Hospitals and Laboratories
Specialty Clinics
Academic and Research Centers
Others

Market Size & Forecast (2024-2031), By Region, USD Billion

North America
- US
- Canada
Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
Latin America
Middle East & Africa

Introduction
- Introduction
- Market Scope
  - Market Definition
  - Segments Covered
  - Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2026-2027)
Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
  - Bottom-Up Approach
  - Top-Down Approach
- Market Forecasting
Executive Summary
- Liquid Biopsy Market Snapshot (2026-2031)
- Segment Overview
- Regional Snapshot
- Competitive Insights

Market Overview
- Market Dynamics
  - Drivers
    - Rising global cancer incidence and growing demand for early cancer detection
    - Increasing adoption of precision medicine and targeted therapies
    - Advancements in NGS, PCR, and multi-omics technologies
    - Growing preference for minimally invasive diagnostic procedures
    - Expanding applications in treatment monitoring and recurrence detection
    - Increasing use of liquid biopsy in companion diagnostics and clinical trials
  - Restraints
    - Limited clinical validation and lack of assay standardization
    - High cost of advanced liquid biopsy and NGS-based testing
    - Reimbursement and regulatory approval challenges
    - Sensitivity limitations in detecting early-stage cancers
  - Opportunities
    - Expansion of multi-cancer early detection (MCED) testing
    - Growing demand for minimal residual disease (MRD) monitoring
    - Increasing adoption across emerging healthcare markets
    - Integration of AI and bioinformatics for genomic interpretation
  - Key Market Trends
    - Growing focus on MRD and longitudinal cancer monitoring
    - Increasing strategic partnerships between pharma and diagnostics companies
    - Rising adoption of multi-omics liquid biopsy platforms
    - Expansion of blood-based cancer screening programs globally
  - Unmet Market Needs
  - Industry Speaks

Global Liquid Biopsy Market Size & Forecast (2024-2031), By Product & Services, USD Billion
- Introduction
- Kits & Reagents
- Instruments
- Software & Services

Global Liquid Biopsy Market Size & Forecast (2024-2031), By Technology, USD Billion
- Introduction
- Next-Generation Sequencing (NGS)
- PCR & Digital PCR (dPCR)
- Others

Global Liquid Biopsy Market Size & Forecast (2024-2031), By Biomarker Type, USD Billion
- Introduction
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA)
- Cell-Free DNA (cfDNA)
- Exosomes/Microvesicles
- Others

Global Liquid Biopsy Market Size & Forecast (2024-2031), By Sample Type, USD Billion
- Introduction
- Blood
- Urine
- Others

Global Liquid Biopsy Market Size & Forecast (2024-2031), By Application, USD Billion
- Introduction
- Oncology
  - Lung Cancer
  - Breast Cancer
  - Colorectal Cancer
  - Prostate Cancer
  - Others
- Non-Cancer Applications
  - Prenatal Testing
  - Transplant Monitoring
  - Infectious Diseases
  - Neurological Disorders

Global Liquid Biopsy Market Size & Forecast (2024-2031), By End User, USD Billion
- Hospitals and Laboratories
- Specialty Clinics
- Academic and Research Centers
- Others

Global Liquid Biopsy Market Size & Forecast (2024-2031), By Region, USD Billion
- Introduction
- North America Liquid Biopsy Market Size & Forecast (2024-2031), By Country, USD Billion
  - US
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
  - Canada
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
- Europe Liquid Biopsy Market Size & Forecast (2024-2031), By Country, USD Billion
  - UK
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
  - Germany
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
  - France
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
  - Italy
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
  - Spain
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
  - Rest of Europe
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
- Asia Pacific (APAC) Liquid Biopsy Market Size & Forecast (2024-2031), By Country, USD Billion
  - China
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
  - Japan
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
  - India
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
  - Rest of Asia Pacific
    - Market Size & Forecast, By Product & Services (USD Billion)
    - Market Size & Forecast, By Technology (USD Billion)
    - Market Size & Forecast, By Biomarker Type (USD Billion)
    - Market Size & Forecast, By Sample Type (USD Billion)
    - Market Size & Forecast, By Application (USD Billion)
    - Market Size & Forecast, By End User (USD Billion)
- Latin America (LATAM) Liquid Biopsy Market Size & Forecast (2024-2031), USD Billion
  - Market Size & Forecast, By Product & Services (USD Billion)
  - Market Size & Forecast, By Technology (USD Billion)
  - Market Size & Forecast, By Biomarker Type (USD Billion)
  - Market Size & Forecast, By Sample Type (USD Billion)
  - Market Size & Forecast, By Application (USD Billion)
  - Market Size & Forecast, By End User (USD Billion)
- Middle East & Africa (MEA) Liquid Biopsy Market Size & Forecast (2024-2031), USD Billion
  - Market Size & Forecast, By Product & Services (USD Billion)
  - Market Size & Forecast, By Technology (USD Billion)
  - Market Size & Forecast, By Biomarker Type (USD Billion)
  - Market Size & Forecast, By Sample Type (USD Billion)
  - Market Size & Forecast, By Application (USD Billion)
  - Market Size & Forecast, By End User (USD Billion)

Global Liquid Biopsy Market, Clinical Utility Analysis (Qualitative)
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
- MRD Monitoring

Competitive Landscape
- Key Players and their Competitive Positioning
  - Key Player Comparison
  - Segment-wise Player Mapping
  - Market Share Analysis (2025)
  - Company Categorization Matrix
    - Dominants/Leaders
    - New Entrants
    - Emerging Players
    - Innovative Players
  - Key Strategies Assessment, By Player (2023-2026)
    - New Product/Service Launch
    - Partnerships, Agreements, & Collaborations
    - Mergers & Acquisitions
    - Geographic Expansion

Company Profiles*

(Business Overview, Financial Performance**, Products Offered, Recent Developments)

Hoffmann-La Roche Ltd
Illumina, Inc.
Guardant Health, Inc.
Myriad Genetics, Inc.
Natera, Inc.
Exact Sciences Corporation
QIAGEN
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Thermo Fisher Scientific Inc.
Other Prominent Players

Note: *Indicative list

**For listed companies

The study has been compiled based on extensive primary and secondary research.

Secondary Research (Indicative List)

Liquid Biopsy Market - Secondary Research

Primary Research

To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.

Supply Side Stakeholders:

Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants

Demand Side Stakeholders:

Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers, and others

Breakdown of Primary Interviews

Liquid Biopsy Market - Primary Interviews

Market Size Estimation

Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts

Liquid Biopsy Market Size Estimation

To learn more about this report, download the PDF brochure

Liquid Biopsy Market Size Estimation 2

Data Triangulation

Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data

Liquid Biopsy Market - Data Triangulation

Global Liquid Biopsy Market Segmentation

Market Size & Forecast (2024-2031), By Product & Service, USD Billion
- Kits & Reagents
- Instruments
- Software & Services

Market Size & Forecast (2024-2031), By Technology, USD Billion
- Next-Generation Sequencing (NGS)
- PCR & Digital PCR (dPCR)
- Others

Market Size & Forecast (2024-2031), By Biomarker Type, USD Billion
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA)
- Cell-Free DNA (cfDNA)
- Exosomes/Microvesicles
- Others

Market Size & Forecast (2024-2031), By Sample Type, USD Billion
- Blood
- Urine
- Others

Market Size & Forecast (2024-2031), By Application, USD Billion
- Oncology
  - Lung Cancer
  - Breast Cancer
  - Colorectal Cancer
  - Prostate Cancer
  - Others
- Non-Cancer Applications
  - Prenatal Testing
  - Transplant Monitoring
  - Infectious Diseases
  - Neurological Disorders

Market Size & Forecast (2024-2031), By End User, USD Billion
- Hospitals and Laboratories
- Specialty Clinics
- Academic and Research Centers
- Others

Market Size & Forecast (2024-2031), By Region, USD Billion
North America
- US
- Canada
Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
Latin America
Middle East & Africa

Frequently Asked Questions (FAQs)

What is the growth rate of the liquid biopsy market?

The liquid biopsy market is set to witness a growth rate of 12% during the forecast period from 2026 to 2031

What are the key trends defining the market?

Integration of AI and bioinformatics in genomic analysis, commercialization of multi-cancer early detection (MCED) tests, increasing pharma-diagnostic collaborations, and growing focus on ultrasensitive ctDNA and MRD testing platforms are major trends in the liquid biopsy market

What are the major factors impacting the market growth?

Rising global cancer incidence, increasing adoption of precision oncology, advancements in NGS and dPCR technologies, growing demand for non-invasive diagnostics, expanding MRD monitoring applications, and increasing regulatory approvals are some of the key factors driving the liquid biopsy market

Who are the major players operating in the market?

Some of the major players operating in the liquid biopsy market include F. Hoffmann-La Roche Ltd (Switzerland); Illumina, Inc. (US); Guardant Health, Inc. (US); Myriad Genetics, Inc. (US); Natera, Inc. (US); Exact Sciences Corporation (US); QIAGEN (the Netherlands); Bio-Rad Laboratories, Inc. (US); Sysmex Corporation (Japan); and Thermo Fisher Scientific Inc. (US); among others

What are the opportunities prevailing in the market?

Expanding adoption of liquid biopsy in early cancer screening, MRD monitoring, companion diagnostics, multi-omics testing, and emerging non-oncology applications such as prenatal and transplant monitoring offering numerous growth opportunities for companies operating in the liquid biopsy market

Features of the Report

Comprehensive Market Coverage
Market Size and Forecast
Geographic & Segment Deep Dives
Strategic Insights & Competitive Landscape
Timely & Updated Data
Growth Indicators & Future Outlook
Quick Turnaround on Queries
Analyst Support
Report Customization Available
Reports in PDF & Excel

Order Report

Global Liquid Biopsy Market Size, Share, Growth & Trends Report Segmented by Technology (NGS, dPCR), Biomarker (ctDNA, cfDNA, CTCs), Application (Lung, Breast, Colorectal, Prostate, Prenatal), Sample (Blood, Urine), Product & Service, End-user, Analysis & Regional Forecast to 2031

Advancements in NGS, PCR, and multi-omics technologies drives the liquid biopsy market

Growing demand for minimal residual disease (MRD) monitoring presents a significant growth opportunity

Competitive Landscape Analysis

Growth strategies adopted by players to establish their foothold in the liquid biopsy market

Report Scope

Global Liquid Biopsy Market Segmentation

Market Size & Forecast (2024-2031), By Product & Service, USD Billion

Market Size & Forecast (2024-2031), By Technology, USD Billion

Market Size & Forecast (2024-2031), By Biomarker Type, USD Billion

Market Size & Forecast (2024-2031), By Sample Type, USD Billion

Market Size & Forecast (2024-2031), By Application, USD Billion

Market Size & Forecast (2024-2031), By End User, USD Billion

Market Size & Forecast (2024-2031), By Region, USD Billion

Secondary Research (Indicative List)

Primary Research

Breakdown of Primary Interviews

Market Size Estimation

Data Triangulation

Frequently Asked Questions (FAQs)

Features of the Report

Quick Enquiry Form